References
- 1. Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D., Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trialsPLoS One. 2017 Sep 21;12(9):e0184597. doi: 10.1371/journal.pone.018459710.1371/journal.pone.0184597560820628934265
- 2. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-36. pmid:16250051.10.1002/hep.2093316250051
- 3. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma. Gastroenterology. 2016;150(4):835-53. pmid:26795574.10.1053/j.gastro.2015.12.04126795574
- 4. Ray CE Jr., Brown AC, Green TJ, Winston H, Curran C, Kreidler SM, et al. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. AJR American journal of roentgenology. 2015;204(2):440–7. pmid:25615768.10.2214/AJR.14.1284425615768
- 5. Fu Y, Zhao X, Yun Q, Zhu X, Zhu Y, Li Q, et al. Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. International journal of clinical and experimental medicine. 2015;8(7):10388-400. pmid:26379829.
- 6. Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2016:1-6. pmid:26794414.
- 7. Ni JY, Xu LF, Wang WD, Sun HL, Chen YT., Conventional Transarterial Chemoembolization vs Microsphere Embolization in Hepatocellular Carcinoma: A Meta-Analysis, World J Gastroenterol. 2014 Dec 7;20(45):17206-17. doi: 10.3748/wjg.v20.i45.17206.10.3748/wjg.v20.i45.17206425859325493037
- 8. Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am. 2014;23:289-311.10.1016/j.soc.2013.10.00624560111
- 9. Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373.10.1007/s11912-013-0373-x392145124488546
- 10. Aubé C, Bouvier A, Lebigot J, Vervueren L, Cartier V, Oberti F. Radiological treatment of HCC: interventional radiology at the heart of management, Diagn Interv Imaging. 2015;96:625-636.
- 11. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma, J Hepatol. 2018;69:182-236.
- 12. Delicque J, Hermida M, Piron L, Allimant C, Belgour A, Pageaux GP, Ben Bouallegue F, Assenat E, Mariano-Goulart D, Guiu B, Cassinotto C. Intra Arterial Treatment of Hepatocellular Carcinoma: Comparison of MELD Score Variations Between Radio-Embolization and Chemo-Embolization, Diagn Interv Imaging. 2019 Nov;100(11):689-697. doi: 10.1016/j.diii.2019.05.006.10.1016/j.diii.2019.05.00631281074
- 13. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol. 2019;30:871-873.
- 14. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC, J Hepatol. 2012;56:75-87.
- 15. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nature reviews Disease primers. 2016;2:16018. pmid:27158749.10.1038/nrdp.2016.1827158749
- 16. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016. pmid:26765068.10.1002/hep.2845326765068
- 17. Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016. pmid:26965785.10.1016/j.dld.2016.02.005
- 18. Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health. 2013;16:760-768.10.1016/j.jval.2013.03.1630
- 19. Leelawat K, Laisupasin P, Kiatdilokrut A, Pongtongpool T, Narong S, Samkhumphim N, Ket-Horm S. The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE). J Med Assoc Thai. 2008;91:1539-1543.
- 20. Chen C, Wang J, Liu R, Qian S. RNA interference of hypoxia-inducible factor-1 alpha improves the effects of transcatheter arterial embolization in rat liver tumors. Tumour Biol. 2012;33:1095-1103.10.1007/s13277-012-0349-8
- 21. Jia ZZ, Jiang GM, Feng YL. Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 2011;26:158-162.10.1016/S1001-9294(11)60041-2
- 22. Winiarski BK, Wolanska KI, Rai S, Ahmed T, Acheson N, Gutowski NJ, Whatmore JL. Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling. Transl Oncol. 2013;6:703-714.10.1593/tlo.13529389070524466373
- 23. Li J, Xu Y, Long XD, Wang W, Jiao HK, Mei Z, Yin QQ, Ma LN, Zhou AW, Wang LS. Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer Cell. 2014;25:118-131.10.1016/j.ccr.2013.12.00824434214
- 24. Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J, Softic A, Muminovic Z, Rifatbegovic A, Begic L. Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a. Int J Breast Cancer. 2013;2013:746749.10.1155/2013/746749387667724416596
- 25. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, Mulcahy M, Liu D, Chrisman H, Resnick S. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522-529.10.1007/s00270-005-0171-416729228
- 26. Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244-1250.10.1016/j.jhep.2012.07.01722824821
- 27. van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, Vaninbroukx J, Nevens F, Verslype C. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie. 2011;34:368-376.10.1159/00032960221734423
- 28. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.10.1053/j.gastro.2009.09.006
- 29. Hawkins CM, Kukreja K, Geller JI, Schatzman C, Ristagno R. Radioembolisation for treatment of pediatric hepatocellular carcinoma. Pediatr Radiol. 2013;43:876-88110.1007/s00247-012-2568-y
- 30. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747-1752.10.1002/cncr.10407
- 31. Siramolpiwat S, Punjachaipornpon T, Pornthisarn B, Vilaichone RK, Chonprasertsuk S, Tangaroonsanti A, Bhanthumkomol P, Phumyen A, Yasiri A, Kaewmanee M., N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization, Dig Dis Sci. 2019 Nov;64(11):3337-3345. doi: 10.1007/s10620-019-05652-010.1007/s10620-019-05652-0
- 32. Tasneem AA, Abbas Z, Luck NH, Hassan SM, Faiq SM. Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events. J Pak Med Assoc. 2013;63:239-244.
- 33. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747-1752.10.1002/cncr.10407
- 34. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:321-326.10.1016/S1051-0443(07)61911-3
- 35. Jun CH, Ki HS, Lee HK, et al. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol. 2013;19:284-289.10.3748/wjg.v19.i2.284354755723345952
- 36. Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA. Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford). 2015;17:1137-1144.10.1111/hpb.12487464436726374137
- 37. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64:1403-1415.10.1016/j.jhep.2016.02.00426867490
- 38. Yamaguchi K, Itoh Y, Yokomizo C, et al. Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-fed db/db mice. Lab Invest. 2011;91:609–61810.1038/labinvest.2011.221321532
- 39. Lauterburg BH, Corcoran GB, Mitchell JR. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest. 1983;71:980-991.10.1172/JCI1108534369566833497
- 40. Camma C, Schepis F, Orlando A et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47-54.10.1148/radiol.224101126212091661
- 41. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.10.1053/jhep.2003.5004712540794
- 42. Marelli L, Stigliano R, Triantos C et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25.10.1007/s00270-006-0062-317103105
- 43. Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA., Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma, HPB (Oxford). 2015 Dec;17(12):1137-44. doi: 10.1111/hpb.12487.10.1111/hpb.12487464436726374137
- Li H, Wu F, Duan M, Zhang G., Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history. A comparison of efficacy and safety. Medicine (Baltimore). 2019 May;98(21):e15314. doi: 10.1097/MD.0000000000015314.10.1097/MD.0000000000015314657123931124925